LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, announced that GlaxoSmithKline (NYSE: GSK) has submitted a regulatory application for its malaria vaccine candidate, RTS,S, to the European Medicines Agency (EMA), and it has been accepted for regulatory review. RTS,S contains Agenus’ QS-21 Stimulon® adjuvant, which is part of GSK’s AS01 proprietary adjuvant system. Adjuvants can enhance the immune response when used in combination with antigens in vaccines.
Help employers find you! Check out all the jobs and post your resume.